ALAchim H. Lauruschkat

Achim H. Lauruschkat

*This is an algorithmically generated author record based on publicly available information.

Achim H. Lauruschkat has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Alexander A. Albert

    Department of Cardiac, Thoracic, and Vascular Surgery, Heart Institute Lahr/Baden, Lahr, Germany

    2 shared publications
  • Bert Arnrich

    Neuroinformatics Group, Faculty of Technology, Bielefeld University, Bielefeld, Germany

    2 shared publications
  • Berthold Amann

    Franziskus Hospital Berlin, Berlin, Germany

    2 shared publications
  • J. Ennker

    Herzzentrum Lahr/Baden

    2 shared publications
  • Tejas Alexander

    Department of Anaesthesiology, Heart Institute Lahr/Baden, Lahr, Germany

    2 shared publications
  • Ulrich P. Rosendahl

    Department of Cardiac, Thoracic, and Vascular Surgery, Heart Institute Lahr/Baden, Lahr, Germany

    2 shared publications

Latest Publications

  • Diabetes mellitus as a risk factor for pulmonary complications after coronary bypass surgery

    by Achim H. Lauruschkat, Bert Arnrich, Alexander A. Albert, Jörg A. Walter, Berthold Amann, Ulrich P. Rosendahl, Tejas Alexander, Jürgen Ennker


  • Erfahrungen mit Diabetikern in der Koronarchirurgie—

    by Med. A. H. Lauruschkat, A. Albert, B. Arnrich, S. Bauer, F. Dalladaku, I. C. Ennker, U. Rosendahl, J. Ennker


  • Prevalence and Risks of Undiagnosed Diabetes Mellitus in Patients Undergoing Coronary Artery Bypass Grafting

    by Achim H. Lauruschkat, Bert Arnrich, Alexander A. Albert, Jörg A. Walter, Berthold Amann, Ulrich P. Rosendahl, Tejas Alexander, Jürgen Ennker

    Background— Numerous studies have shown that diabetes mellitus (DM) is not identified and, consequently, inadequately treated in a substantial proportion of the patients in the general population. We know very little about the extent and the consequences of undiagnosed diabetes in the risk group of patients with coronary heart diseases. The objective of this study was therefore to determine the prevalence and the risks of undiagnosed DM among patients with coronary artery bypass. Methods and Results— The data of 7310 patients who have undergone coronary bypass operations between 1996 and 2003 were analyzed. Depending on their diagnosis on admission and their fasting plasma glucose (FPG) level, these patients were classified as known diabetics, undiagnosed diabetics (FPG ≥126 mg/dL), or as nondiabetics (FPG P P 1 day (5.6% versus 10.5% versus 7.4%; P P Conclusions— This study is the first to publish the prevalence of undiagnosed diabetes mellitus in cardiac surgery. During the perioperative and postoperative courses, these patients displayed a substantially higher morbidity and mortality rate.


  • Diabetes Mellitus in Coronary Artery Surgery: Therapeutic Strategies in the Light of Recent Studies

    by A. H. Lauruschkat, J. Ennker

    Advances in percutaneous coronary revascularization have meant that, increasingly, patients with multivessel diseases are initially treated with the methods of interventional cardiology. Ongoing studies involving new stent coatings and optimized anti-thrombotic therapies could help to lower future restenosis rates and improve the success rate of stenting. Thrombocyte glycoprotein IIb/IIIa receptor blockers have already been shown to reduce the rate of acute PTCA complications in high-risk patients and could have a sustained impact on the long-term prognoses for PTCA patients. However, for diabetic patients with coronary multivessel diseases, coronary artery bypass grafting using arterial grafts as the initial revascularization method must be given preference over other therapy methods. Consequently, this group of patients is bound to grow in importance in cardiac surgery. The advances made in percutaneous coronary revascularization and in coronary surgery call for further prospective, controlled, randomized clinical studies in order to establish the best possible treatment strategy for patients with diabetes. It should be noted, however, that the therapeutic effect of myocardial revascularization is generally limited to individual coronary-arterial segments, whereas the pathological process of atherosclerosis is rather diffuse. The surgical strategy should therefore be seen as part of an overall strategy which encompasses other forms of treatment (e.g. intensive efforts to improve control of blood glucose level, blood pressure, and cholesterol level) in order to arrest the general progression of the disease and to reduce the risk of myocardial infarction and death.